Pioglitazone: Pioglitazone decreases insulin resistance in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Unlike sulfonylureas, pioglitazone is not an insulin secretagogue. Pioglitazone is a potent and highly selective agonist for peroxisome proliferator-activated receptor-gamma (PPAR?). It improves glycemic control by improving insulin sensitivity at key sites of insulin resistance namely adipose tissues, skeletal muscles and liver. Insulin resistance is known to play a major role in the pathogenesis of type 2 diabetes.Metformin HCl: Metformin HCI is an anti-hyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycemia.
Add additional product information here.
Add your shipping and returns information here.